Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

The purpose of this study is to demonstrate the comparability of ianalumab exposure
following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL
auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to
evaluate the safety and tolerability of ianalumab following the s.c. administration of
both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or
systemic lupus erythematosus (SLE).

A second optional cohort may be included with the objective of demonstrating the
comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS)
and 2 x 1 mL PFS. The study consists of the following periods:

Screening period (up to 4 weeks):

Following the signing of the informed consent, participants will be assessed for
eligibility during this period of up to 4 weeks.

Treatment Period 1 + Treatment Period 2, (Week 0 to Week 24):

After completion of the screening period, eligible participants will be randomized at the
Baseline visit (Week 0) to one of the 2 treatment sequences (treatment switch at Week 12)
in a ratio of 1:1 described below:

- Cohort 1:

- Sequence 1: ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment
Period 1 and ianalumab 300 mg s.c. (1 x 2 mL AI) monthly + SoC in Treatment
Period 2

- Sequence 2: ianalumab 300 mg s.c. (1 x 2 mL AI) monthly + SoC in Treatment
Period 1 and ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment
Period 2

- Cohort 2 (Optional):

- Sequence 1: ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment
Period 1 and ianalumab 300 mg s.c. (1 x 2 mL PFS) monthly + SoC in Treatment
Period 2

- Sequence 2: ianalumab 300 mg s.c. (1 x 2 mL PFS) monthly + SoC in Treatment
Period 1 and ianalumab 300 mg s.c. (2 x 1 mL PFS) monthly + SoC in Treatment
Period 2 In addition, within each sequence, participants will be further
randomized to one of the predetermined injection sites with equal allocation,
resulting in a total randomization combination of four (2 sequences x 2
injection sites) for Cohort 1 and six (2 sequences x 3 injection sites) for
Cohort 2, respectively.

Extended Treatment period (Week 24 to Week 72): After completion of Week 24 assessment,
all participants (who did not discontinue during treatment period) will have the option
to enter the extended treatment period to receive ianalumab 300 mg s.c. (Cohort 1: 2 mL
AI; Cohort 2: 2 mL PFS) monthly up to Week 68. The end of treatment (EOT) visit will be
performed 4 weeks after the last study treatment administration, i.e., at Week 72.

Mandatory Post-Treatment safety follow-up period (from Week 72 to Week 88): Participants
who completed the last study treatment or prematurely discontinued from study treatment
will enter the post-treatment safety follow-up period.

Conditional Post-Treatment safety follow-up period (from Week 88 to Week 176)
Post-treatment follow-up will be performed until B-cell recovery or up to 2 years. B-cell
recovery is defined when CD19+ B-cell counts return to >= 50 cells/μL or >= 80% of
baseline value, whichever occurs earlier.